Google's DeepMind, the British artificial intelligence firm behind the human-besting AlphaGo software, launched a healthcare platform in partnership with the U.K.'s Moorfields Eye Hospital and Royal Free London in 2015. Starting this month, doctors and nurses at Musgrove Park will get DeepMind's Streams app for iPhone, which helps spot early signs of acute kidney injury. "This is all about early detection of seriously unwell patients so that we can immediately escalate care, ensure a very rapid response, and make sure they are treated quickly by the right specialist doctor," Luke Gompels, a consultant in medicine at Musgrove Park Hospital, told the BBC. Last year, it acquired Hark, a task management app optimized for hospital environments that was co-developed by students from Imperial College London and the National Institute for Health Research.
A deal between Google's artificial intelligence firm DeepMind and the UK's NHS had serious "inadequacies", an academic paper has suggested. More than a million patient records were shared with DeepMind to build an app to alert doctors about patients at risk of acute kidney injury (AKI). In a statement, the ICO told the BBC: "Our investigation into the sharing of patient information between the Royal Free NHS Trust and Deep Mind is close to conclusion. It revealed that more than 26 doctors and nurses at the Royal Free are now using Streams and that each day it alerts them to 11 patients at risk of AKI.
Google DeepMind, the tech giant's London-based company most famous for its groundbreaking use of artificial intelligence, is developing a software in partnership with NHS hospitals to alert staff to patients at risk of deterioration and death through kidney failure. In early pilots at St Mary's Hospital, part of Imperial College Healthcare NHS Trust, where Darzi is a consultant surgeon, they found medical staff responded 37% faster when alerted by the Hark app than when they used pagers. Everybody has a smartphone ... but the people saving lives every day are hampered by using desktop computers Despite DeepMind's expertise in artificial intelligence (AI) and machine learning, the smartphone app being piloted does not use either technology. "But the people doing incredible work saving lives every day are hampered by using desktop computers and software designed a long time ago."
The Royal Free London NHS Foundation Trust has announced a five-year deal with DeepMind, which became established as one of the leaders in the field when it was acquired by Google in 2014. We want to lead the way in healthcare technology and this new clinical app will enable us to provide safer and faster care to patients – which will save lives. "Doctors and nurses currently spend far too much time on paperwork, and we believe this technology could substantially reduce this burden, enabling doctors and nurses to spend more time on what they do best - treating patients." Royal Free London and DeepMinds plan to further develop Streams, so it will provide instantaneous alerts to doctors and nurses, and be used for dealing with other patient conditions such as sepsis and organ failure.
The research team hypothesized that a targeted panel of urinary biomarkers reflecting initial resident and inflammatory cell activation (cytokines), signals for homing to the kidney (chemokines), activation of inflammatory cells (growth factors), and damage to resident cells, combined with artificial intelligence/machine learning modeling, might provide an early LN decision-support tool that could predict outcomes better than standard biomarkers alone. Outcome models using novel biomarkers plus traditional clinical markers demonstrated greater AUC and significance compared to models developed with traditional markers alone ([AUC 0.79; P 0.001] vs. [AUC 0.61; P 0.05], respectively). The combined models also demonstrated greater power to correctly predict LN therapy outcomes (responder versus non-responder) than models using only traditional markers (76% vs. 27%, respectively [P 0.002]). The team identified chemokines, cytokines, and markers of cellular damage as most predictive of LN therapy response.
The team built on previous work, in which they identified more than 130 proteins that differed between fluid samples collected from patients with prostate-confined tumors and those with tumors that had spread beyond the gland. The team analyzed urine samples from 50 patients with prostate cancer -- 37 with prostate-confined tumors and 13 with tumors that spread -- and 24 healthy controls. Twenty-four of these showed differences between patients with cancer and healthy controls, suggesting these markers could be useful for diagnosis. The team next analyzed urine samples collected from a second, independent group of 117 healthy controls and 90 patients with prostate cancer (61 with stage T2, prostate-confined cancer and 29 with stage T3, cancer that's spread to nearby tissues called seminal vesicles).
DeepMind and the Royal Free have also been criticized for not approaching the UK's medicines and healthcare devices regulator, the MHRA, prior to using the Streams app in hospitals. However earlier this month, New Scientist obtained a copy of the data-sharing agreement between DeepMind and the Royal Free -- which revealed that rather than only getting access to data from patients directly affected by AKI, the agreement in fact shared all hospital admissions data, extending back a full five years. It's this secondary usage scenario of the data-sharing agreement that has drawn specific criticism from patient data privacy groups, among others, given that the data in question is personally identifiable -- which normally, under NHS regulations, can only be shared with third parties with implied consent if it is to be used for direct patient care. The Royal Free spokesman declined to answer these specific questions, pointing to an online Q&A that was published on the same day the MHRA contacted Google to discuss the app.
There are currently 58 of these surgical systems in the NHS, undertaking operations for a variety of common complaints, from the removal of kidney and bladder cancers to basic heart surgery - though their main use is in surgical removal of the prostate gland and surrounding tissue in men with prostate cancer. There are currently 58 of these surgical systems in the NHS, undertaking operations for a variety of common complaints, from the removal of kidney and bladder cancers to basic heart surgery - though their main use is in surgical removal of the prostate gland and surrounding tissue in men with prostate cancer. The researchers tested their robot against manual surgery by expert surgeons, carrying out a simple bowel procedure called a laparoscopy, and robot-assisted surgery with the da Vinci Surgical System (pictured). The researchers tested their robot against manual surgery by expert surgeons, carrying out a simple bowel procedure called a laparoscopy, and robot-assisted surgery with the da Vinci Surgical System.
The document – a data-sharing agreement between Google-owned artificial intelligence company DeepMind and the Royal Free NHS Trust – gives the clearest picture yet of what the company is doing and what sensitive data it now has access to. "The data-sharing agreement gives Google access to information on millions of NHS patients" DeepMind announced in February that it was working with the NHS, saying it was building an app called Streams to help hospital staff monitor patients with kidney disease. This is the first we've heard of DeepMind getting access to historical medical records, says Sam Smith, who runs health data privacy group MedConfidential. The document also reveals that DeepMind is developing a platform called Patient Rescue, which will provide data analytics services to NHS hospital trusts.
The encrypted information includes the names and medical histories of every patient who had stayed in hospital overnight or attended A&E in the past five years. Trust managers approached Google to develop the app and then handed over the patient files after signing an'information-sharing agreement' last year. The app will process blood test results and immediately inform doctors in charge of their care if they are at risk. A trust spokesman said: 'The Royal Free London approached DeepMind with the aim of developing an app that improves the detection of acute kidney injury by immediately reviewing blood test results for signs of deterioration, then sending an alert and the results to the most appropriate clinician via a dedicated handheld device.